Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351
In development
Reference number: GID-TA11333
Expected publication date: TBC
Following a request from the company, further information regarding the timelines for this appraisal will be available in due course. NICE will provide an update as and when the situation changes.
This appraisal has therefore been paused and the Committee discussion scheduled for March 2026 will not take place.